Clinical observation on the treatment of mild active Crohn′s disease by combining Jiawei Lizhong Decoction with mesalazine

doi:10.3877/cma.j.issn.2095-2015.2023.04.002

Abstract

Abstract:

Objective

To investigate the clinical efficacy of Jiawei Lizhong Decoction combined with mesalazine in the treatment of mild active Crohn′s disease.

Methods

A total of 100 patients with mild active Crohn′s disease admitted to Daqing Traditional Chinese Medicine Hospital from January 2019 to January 2022 were included, and all patients were divided into a control group(n=50)and observation group(n=50)according to the randomized alphabetical method.The control group was treated with mesalazine, and the experimental group was treated with Jiawei Lizhong Decoction on top of the treatment in the control group.The Chinese medicine evidence score, Crohn′s disease activity index(CDAI)score and Crohn′s disease endoscopic index of severity(CDEIS)score, inflammatory factors(IL-6, TNF-α)levels, immune function indexes(serum CD3+, CD4+, CD4+ /CD8+ ), and incidence of adverse reactions were compared before and after treatment in the two groups.

Results

There were no statistically significant differences the general baseline informations(gender, age, BMI, disease duration)between the control and observation groups(P>0.05), The overall effective rate of the observation group was higher than that of the control group, (P<0.05). After treatment, the CDAI and CDEIS scores of patients in both groups decreased, and the experimental group was lower than the control group(P<0.05). There was no statistically significant difference inthe total incidence of adverse reactions between the two groups(P>0.05).

Conclusion

Jiawei Lizhong Decoction combined with mesalazine is effective in treatment of mild active Crohn′s disease, which can effectively relieve the clinical symptoms and reduce the inflammatory response in patients with mild active Crohn′s diseas

Key words: Crohn′s disease, Jiawei Lizhong Decoction, Mesalazine, Clinical efficacy, Adverse reactions

Xiaodong Yu, Dehua Li, Shan Gao, Xin Xu. Clinical observation on the treatment of mild active Crohn′s disease by combining Jiawei Lizhong Decoction with mesalazine[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 199-202.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2023.04.002

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2023/V13/I04/199

Figures/Tables 6

References 22

1	Anne G，Jacqueline K，Gieri C．Crohn Disease in Granulomatous Appendicitis Revisited：And Yersinia infection？[J]．Am J Surg Pathol，2023，47(5)：630-631.
2	Ernst F．Treatment withdrawal in Crohn′s disease：slowly becoming clearer[J]．Lancet Gastroenterol Hepatol，2023，8(3)：200-201.
3	朱梦佳，王淋，杨慧萍．中医治疗克罗恩病临床研究进展[J]．中医研究，2020，33(1)：74-77.
4	刘洋，何运胜，赵平武，等．克罗恩病的临床表现及中西医分型研究进展[J]．现代消化及介入诊疗，2023，28(3)：390-394.
5	中华医学会消化病学分会炎症性肠病学组．炎症性肠病诊断与治疗的共识意见[J]．中华消化杂志，2018，38(5)：292-311.
6	张毅，周进．益肝扶脾方联合甲氨蝶呤对肝郁脾虚型克罗恩病中重度患者IL-23/Th17炎症通路的影响[J]．四川中医，2021，39(11)：112-115.
7	郑伟伟．补中益气汤联合英夫利西单抗治疗活动性克罗恩病临床研究[J]．新中医，2023，55(2)：23-27.
8	周培，沈玉婷，沈卫东．英夫利西单抗治疗克罗恩病的疗效及安全性分析[J]．系统医学，2023，8(3)：119-122.
9	Roda G，Chien Ng S，Kotze PG，et al.Crohn′s disease[J]．Nat Rev Dis Primers，2020，6(1)：26.
10	Popa SL，Pop C，Dumitrascu DL.Diet Advice for Crohn′s Disease：FODMAP and Beyond[J]. Nutrients，2020，12(12)：3751.
11	Sulz MC，Burri E，Michetti P，et al.Treatment Algorithms for Crohn′s Disease[J]. Digestion，2020，101 Suppl 1：43-57.
12	Paglinco SR，Ciciora SL.Extravasation of Intravenous Iron Causing Skin Staining in a Child with Crohn Disease[J]．J Pediatr Gastroenterol Nutr，2023，76(5)：e82.
13	Geldof J，Iqbal N，LeBlanc JF，et al.Classifying perianal fistulising Crohn′s disease：an expert consensus to guide decision-making in daily practice and clinical trials[J]. Lancet Gastroenterol Hepatol，2022，7(6)：576-584.
14	Caio G，Lungaro L，Caputo F，et al.Nutritional Treatment in Crohn′s Disease[J]. Nutrients，2021，13(5)：1628.
15	Vasudevan A，Bruining DH，Loftus EV Jr，et al.Approach to medical therapy in perianal Crohn′s disease[J]. World J Gastroenterol，2021，27(25)：3693-3704.
16	陈颖．克罗恩病的辨证论治及针灸治疗的研究进展[J]．中国中医急症，2019，28(7)：1313-1316.
17	黄智斌，刘奇，刘刚，等．从整合医学角度探讨克罗恩病中医发病机制[J]．医学与哲学(B)，2018，39(9)：71-75.
18	栗梦晓，赵文霞．克罗恩病病因病机探析[J]．山东中医药大学学报，2020，44(4)：396-399.
19	杨鎏，鱼涛．克罗恩病的中医研究进展[J]．中医药学报，2023，51(5)：88-93.
20	马文校，刘亿托，罗艳贞，等．理中汤加味治疗慢性肠炎脾胃虚弱证临床观察[J]．深圳中西医结合杂志，2021，31(15)：67-68.
21	陈丹，陈洋，李骥，等．血清IL-6与TNF-α在克罗恩病疾病评估中的应用[J]．胃肠病学和肝病学杂志，2020，29(3)：279-284.
22	林芊如，夏宣平，蔡小鸟，等．调节性B细胞和调节性T细胞与英夫利昔单抗治疗克罗恩病临床疗效的关系[J]．中华医学杂志，2020，100(42)：3303-3308.

组别	例数	性别[例(% )]		年龄(岁，±s)	体重指数[例(% )]		病程(年，±s)
组别	例数	男	女	年龄(岁，±s)	>23 kg/m²	≤23 kg/m²	病程(年，±s)
对照组	50	26(52)	24(48)	25.27±2.25	23(46)	27(54)	2.08±0.65
试验组	50	25(50)	25(50)	25.16±2.20	26(52)	24(48)	2.28±0.25
t/χ²	0.04	3.128		0.36	5.325
P	0.841	0.325		0.549	0.493

组别	例数	性别[例(% )]		年龄(岁，±s)	体重指数[例(% )]		病程(年，±s)
组别	例数	男	女	年龄(岁，±s)	>23 kg/m²	≤23 kg/m²	病程(年，±s)
对照组	50	26(52)	24(48)	25.27±2.25	23(46)	27(54)	2.08±0.65
试验组	50	25(50)	25(50)	25.16±2.20	26(52)	24(48)	2.28±0.25
t/χ²	0.04	3.128		0.36	5.325
P	0.841	0.325		0.549	0.493

组别	例数	临床缓解	显著	有效	无效	总有效率
对照组	50	11(22)	18(36)	16(32)	5(10)	45(90)
试验组	50	20(40)	16(32)	13(26)	1(2)	49(98)
χ²		2.613	0.118	0.31	2.667	0.17
P		0.106	0.731	0.578	0.102	0.041

组别	例数	临床缓解	显著	有效	无效	总有效率
对照组	50	11(22)	18(36)	16(32)	5(10)	45(90)
试验组	50	20(40)	16(32)	13(26)	1(2)	49(98)
χ²		2.613	0.118	0.31	2.667	0.17
P		0.106	0.731	0.578	0.102	0.041

组别	例数	CDAI评分				CDEIS评分
组别	例数	治疗前	治疗后	t	P	治疗前	治疗后	t	P
对照组	50	6.78±1.05	5.41±0.65	3.181	<0.05	5.90±1.02	4.96±0.81	2.762	<0.05
试验组	50	7.02±0.95	3.46±0.43	13.182	<0.05	6.01±0.92	3.07±0.62	17.983	<0.05
t		1.20		17.7		0.57		13.1
P		0.23		<0.001		0.57		<0.001

Please choose a citation manager

Content to export